Introduction {#sec1}
============

Tumor necrosis factor (TNF) inhibitor--induced palmoplantar pustulosis (PPP) can present with debilitating, refractory disease that requires changing or stopping anti-TNF agents or adding systemic treatments. Here, we report an update of a previously reported case of severely recalcitrant PPP successfully treated with the Janus kinase (JAK) inhibitor tofacitinib.

Case report {#sec2}
===========

A white woman in her 40s initially presented with vesiculopustules on her palms and soles, clinically diagnosed as PPP, in the setting of adalimumab treatment for Crohn\'s disease. Despite cessation of adalimumab, the patient\'s eruption persisted. Throughout the course of her care, she failed to respond to multiple treatment regimens ([Table I](#tbl1){ref-type="table"}). Eventually, she had complete clearance after 4 doses of ustekinumab 45 mg subcutaneous injections, with remission achieved for several months, and her case was reported in *Archives of Dermatology*.[@bib1]Table ITherapies and treatment responseDate startedDate endedMedicationReason for discontinuationBefore first appointmentJune 2008EfalizumabWorsening of symptomsJune 2008July 2008Cyclosporine 400 mgEsophagitisJuly 2008August 2008Intravenous cyclosporineIssues with midline access, painAugust 2008August 2008Mycophenolic acidWorsening of symptomsAugust 2008October 2008Psoralen plus ultraviolet A with oxsoralen ×8Sustained burn and stopped\
Mild improvementOctober 2008March 2009Topical steroid and oral steroid taperWorsening of symptomsMay 2009July 2009AlefaceptWorsening of symptomsAugust 2009February 2010Cyclosporine 200 mgCreatinine riseOctober 2009February 2010IsotretinoinNo improvementFebruary 2010November 2010Ustekinumab 45 mg ×4 injectionsCompletely clear with residual responseNovember 2010February 2013Topical dapsone, cyclosporineResidual response from ustekinumabFebruary 2013June 2013Cyclosporine 200 mgCreatinine riseJune 2013November 2013Ustekinumab 90 mg ×4 injectionsNo improvementJanuary 2014March 2014AnakinraNational Institutes of Health trial, limited by adverse effects (severe injection site reaction, headache)April 2014July 2014Cyclosporine 200 mgCreatinine riseApril 2014July 2014MethotrexateCreatinine riseSeptember 2014December 2014AcitretinNo improvementSeptember 2014December 2014Cyclosporine 200 mgNausea and vomitingJanuary 2015November 2017ApremilastNo improvement by itself\
Clear in combination with tocilizumab initially\
Ultimately relapsed with residual diseaseMay 2015November 2017TocilizumabNo improvement by itself\
Clear in combination with apremilast initially\
Ultimately relapsed with residual diseaseNovember 2017November 2017Cyclosporine 200 mgFlare requiring short-term cyclosporineDecember 2017December 2017Guselkumab 100 mg ×1 injectionNo improvementJune 2018PresentTofacitinibCompletely clear

Over time, however, the patient experienced worsening of her disease and subsequently failed to improve despite an increased dose of 90 mg ustekinumab. Because of debilitating symptoms, she was intermittently treated with cyclosporine at low doses. She had complete clearance temporarily while taking a combination of apremilast and tocilizumab, but she was unable to be tapered off either medication without a recurrence of symptoms, and she ultimately relapsed with active disease despite combination therapy. She was started on tofacitinib 5 mg tablets twice daily. Since initiation of this medication, her PPP has cleared completely without intermittent flares ([Fig 1](#fig1){ref-type="fig"}, *A*-*D*). During a follow-up period of 1 year after initiation of tofacitinib, she was able to discontinue all other topical and systemic immunosuppressive agents. Her Crohn\'s disease was in remission for the duration of her treatment for PPP, without flares of her gastrointestinal disease on any of the medications.Fig 1The left hand (**A**) before and (**B**) after tofacitinib initiation and the right foot (**C**) before and (**D**) after tofacitinib initiation.

Discussion {#sec3}
==========

Because TNF inhibitor--induced PPP remains a relatively uncommon, understudied phenomenon, its pathophysiology and long-term treatment have not been well established. Here, we present a case of refractory TNF inhibitor--induced PPP that improved with tofacitinib, a JAK inhibitor.

Tofacitinib is an oral JAK inhibitor that inhibits the JAK--signal transducer and activator of transcription pathway, with the greatest effect on JAK1 and JAK3. It decreases the production of a multitude of cytokines, most notably interferon γ, interleukin 6, and interleukin 17A,[@bib2] which have been shown to play a role in the pathogenesis of PPP.[@bib3] However, because tofacitinib has also been implicated as a trigger for PPP, additional cytokines may be involved.[@bib4]

Consistent with our current findings, a previous case report has shown the success of tofacitinib for recalcitrant TNF inhibitor--induced PPP in the setting of rheumatoid arthritis treatment.[@bib5] We recommend consideration of the use of tofacitinib as a potential long-term management agent for refractory TNF inhibitor--induced PPP. We also hope to encourage further investigation of this agent.
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